1. Home
  2. JELD vs VNDA Comparison

JELD vs VNDA Comparison

Compare JELD & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$2.76

Market Cap

243.5M

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$6.76

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
VNDA
Founded
1960
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.5M
289.0M
IPO Year
2017
2006

Fundamental Metrics

Financial Performance
Metric
JELD
VNDA
Price
$2.76
$6.76
Analyst Decision
Hold
Strong Buy
Analyst Count
7
3
Target Price
$4.23
$14.00
AVG Volume (30 Days)
1.6M
1.3M
Earning Date
11-03-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,304,951,000.00
$212,074,000.00
Revenue This Year
N/A
$12.01
Revenue Next Year
N/A
$21.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.12
52 Week Low
$1.70
$3.81
52 Week High
$10.09
$7.05

Technical Indicators

Market Signals
Indicator
JELD
VNDA
Relative Strength Index (RSI) 47.83 66.88
Support Level $2.66 $6.15
Resistance Level $3.00 $7.05
Average True Range (ATR) 0.15 0.45
MACD 0.08 0.09
Stochastic Oscillator 48.99 86.57

Price Performance

Historical Comparison
JELD
VNDA

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: